- Home
- LKFN vs VRDN Comparison
LKFN vs VRDN Comparison
Compare LKFN & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LKFN
- VRDN
- Stock Information
- Founded
- LKFN 1872
- VRDN 2006
- Country
- LKFN United States
- VRDN United States
- Employees
- LKFN N/A
- VRDN N/A
- Industry
- LKFN Major Banks
- VRDN Medical Specialities
- Sector
- LKFN Finance
- VRDN Health Care
- Exchange
- LKFN Nasdaq
- VRDN Nasdaq
- Market Cap
- LKFN 1.3B
- VRDN 1.6B
- IPO Year
- LKFN 1997
- VRDN N/A
- Fundamental
- Price
- LKFN $54.47
- VRDN $13.36
- Analyst Decision
- LKFN Hold
- VRDN Buy
- Analyst Count
- LKFN 1
- VRDN 12
- Target Price
- LKFN $74.00
- VRDN $36.44
- AVG Volume (30 Days)
- LKFN 253.1K
- VRDN 1.1M
- Earning Date
- LKFN 04-25-2025
- VRDN 05-07-2025
- Dividend Yield
- LKFN 3.69%
- VRDN N/A
- EPS Growth
- LKFN N/A
- VRDN N/A
- EPS
- LKFN 3.63
- VRDN N/A
- Revenue
- LKFN $236,773,000.00
- VRDN $302,000.00
- Revenue This Year
- LKFN $13.29
- VRDN N/A
- Revenue Next Year
- LKFN $4.82
- VRDN $20,553.29
- P/E Ratio
- LKFN $14.94
- VRDN N/A
- Revenue Growth
- LKFN N/A
- VRDN N/A
- 52 Week Low
- LKFN $50.74
- VRDN $9.90
- 52 Week High
- LKFN $78.61
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- LKFN 39.47
- VRDN 50.08
- Support Level
- LKFN $51.70
- VRDN $9.90
- Resistance Level
- LKFN $56.96
- VRDN $14.61
- Average True Range (ATR)
- LKFN 2.46
- VRDN 1.12
- MACD
- LKFN 0.33
- VRDN 0.29
- Stochastic Oscillator
- LKFN 42.20
- VRDN 77.81
About LKFN Lakeland Financial Corporation
Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. Lakeland offers a broad range of products and services throughout its Northern and Central Indiana markets. The company offers commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.